已收盤 11-20 16:00:00 美东时间
+0.031
+4.37%
NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma. The findings were presented at the 38th EORTC-NCI-AACR Symp...
11-20 21:07
NuCana plc announced new preclinical data showing that NUC-7738 enhances the anti-cancer activity of carfilzomib, a proteasome inhibitor used to treat multiple myeloma. In three cell models, the combination reduced cell viability to 3% and 26%, exceeding expected results. NUC-7738 alters proteasome function, increasing carfilzomib's inhibition. The findings suggest a potential new mechanism of action for NUC-7738 and support further evaluation in...
11-20 13:00
NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the European Patent Office ("EPO") has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over ...
09-30 20:03
NuCana plc announced that the European Patent Office has granted a key patent for NUC-7738, bringing the total number of issued patents worldwide to over 85. This composition-of-matter patent strengthens the company's intellectual property strategy and commercial protection for NUC-7738, a novel anti-cancer agent in Phase 2 clinical trials. CEO Hugh S. Griffith highlighted the milestone as a testament to the company's science and commitment to pr...
09-30 12:00
Everbright Digital Holding Ltd.涨-13.19%;Sky Quarry, Inc.涨-12.98%;20/20 Biolabs, Inc.涨-11.71%
06-15 08:05
NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster
06-01 20:11
NuCana plc has appointed Ian Webster as Chief Financial Officer, effective June 1, 2026. Ian has served as Interim CFO since June 2025 and joined NuCana in 2019 as Director of Finance. With over 20 years of finance experience, including senior roles in the biopharmaceutical sector, Ian will help shape NuCana's financial strategy as it advances its pipeline, including the Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda for melano...
06-01 12:00